
aTENSION.life
Clinical test offering precise blood pressure hormone analysis using mass spectrometry for enhanced hypertension care.
Date | Investors | Amount | Round |
---|---|---|---|
* | $3.0m | Seed | |
Total Funding | 000k |
Related Content
Atension.life operates in the healthcare diagnostics market, focusing on hypertension care through its proprietary clinical test, ALDO. This test uniquely measures the concentrations of blood pressure hormones Angiotensin I, Angiotensin II, and Aldosterone directly in serum using mass spectrometry LC MS MS. Unlike traditional methods that rely on indirect markers, ALDO provides high sensitivity and specificity, reducing biological and technical variability. The business model targets clinicians, laboratories, and patients, offering a reliable screening tool for primary aldosteronism and assessing the efficacy of antihypertensive therapies. Revenue is generated through the sale of these diagnostic tests, which promise operational simplicity and cost efficiency. The test's ability to deliver precise results with minimal drug interference positions it as a valuable asset in clinical scenarios where medication interference is common. Keywords: hypertension, diagnostics, mass spectrometry, Angiotensin, Aldosterone, serum analysis, blood pressure, clinical test, healthcare, antihypertensive.